At Upstream Bio we strive to reach the source of inflammation and conquer it. Our lead program is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases. We are leveraging our diverse roots and the team’s substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones.

HBM Healthcare Investments AG

Omega Funds

OrbiMed

Samsara BioCapital

Maruho

Access Biotechnology

Altshuler Shaham

TCG Crossover

Decheng Capital

Wellington Management

HBM Partners

Bain Capital Life Sciences

Venrock Healthcare Capital Partners

Enavate Sciences

Upstream Bio

CrUX Dataset

CrUX Top 10m

Twitter Timeline

Chief Medical Officer and Head of Research and Development

Aaron Deykin

Chief Business Officer

Adam Houghton

Co-Founder & Founding President of R&D

Oren Becker

Chief Executive Officer

Samantha Truex

Senior Vice President Regulatory Affairs and Quality

Mersedeh Miraliakbari

Business Management

Arkadeep Sinha

Associate Director, Clinical Operations Lead

Cheryl Knipe

Associate Director, HR Operations

Emily Curtis

Director, Regulatory Affairs

Greg May

Operations

Kathy Drozd

Ron Renaud

Alex Rosen

Edd Fleming

Lisa Fiering

SVP, People and Culture

Michael Gray

Chief Financial Officer and Chief Operating Officer

Eran Perry

Co-Founder and Board Member

Jen Beachell

Chief Operating Officer

Rand Sutherland

Therapeutics Public Companies With Fewer Than 1000 Employees

Waltham Companies that Exited

Northeastern US Companies With Fewer Than 1000 Employees (Top 10K)

Tel Aviv University Alumni Founded Companies

Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. They are clinical-stage monoclonal antibodies that inhibit the TSLP receptor, a validated target located upstream of various signaling cascades that influence a range of immune cells that are important in common and unusual illnesses.

Series B - Upstream Bio

Series A - Upstream Bio

Waltham

Massachusetts

United States

North America

Upstream Bio prices IPO at $17 per share

Upstream Bio raises $255 mln in US IPO

Upstream Bio Announces Pricing of Upsized Initial Public Offering

Upstream Bio, CeriBell, CAMP4 set terms for proposed IPOs

Upstream Bio goes public amid spate of IPOs

Biotechs line up for IPOs in bullish sign for US listings market

Blackstone commits $300M to a former Merck antibody for asthma, COPD

UpStream BPO to hopen an office in Syrdarya region of Uzbekistan

India

Asia

Israel

United Kingdom

Europe

Pakistan

Upstream Bio owns Upstream Bio

Biogen is a biotechnology company that focuses on developing therapies for neurological and autoimmune diseases.

Biogen

BeiGene is a biopharmaceutical company specializing in the development of molecularly targeted and immuno-oncology cancer therapeutics.

BeiGene

Regeneron Pharmaceuticals is a biotechnology company that develops medications for eye diseases, allergic and inflammatory conditions, cancer, and rare diseases.

Regeneron Pharmaceuticals

Precigen is a biopharmaceutical company that focuses on the development of innovative gene and cell therapies for patients with unmet medical needs.

Precigen

ALX Oncology is a clinical-stage immuno-oncology company dedicated to developing therapies that target the CD47 checkpoint pathway.

ALX Oncology

Apellis Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapeutic compounds to treat autoimmune and inflammatory diseases.

Apellis Pharmaceuticals

MorphoSys is a biopharmaceutical company that develops antibody-based drugs for the treatment of cancer, autoimmune diseases, and other serious illnesses.

MorphoSys

Ultivue is a biotechnology company that provides innovative solutions for multiplex tissue biomarker analysis.

Ultivue

Ohana Biosciences is a biotechnology company focused on developing therapies for reproductive health and fertility.

Ohana Biosciences

Matterworks is a biotechnology company that develops innovative solutions for personalized medicine and drug discovery.

Matterworks

Upstream Bio is a biotechnology company focused on developing treatments for inflammatory and allergic diseases.

Regulatory Affairs

Manager, Regulatory Affairs

Associate Director, Regulatory Affairs

Technical Recruiter

Director, Regulatory Affairs at Upstream Bio

Independent Director

CEO, Upstream Bio

Head of Translational Research

Senior Director

Clinical Scientist

Principal Scientist

Senior Scientist

Scientist

Head of Translational Research at Upstream Bio

Ashish Kalra

Director, Clinical Operations Lead

Associate Director, Clinical Trial Lead

Director, Clinical Operations Program Lead

Associate Director, Clinical Operations Study Lead

Sr. Clinical Project Manager

Director, Clinical Operations Lead at Upstream Bio

Rebecca Nuzzo

Senior Medical Director, Clinical Development

Clinical Program Director

Advanced Lung Disease / Lung Transplant Fellowship Director

Medical Director, Lung Transplant Program

Pulmonary and Critical Care Fellow

Transplant Pulmonology | Clinical Development | Wharton MBA

James Lee

Director, Clinical Operations

Associate Director Clinical Operations

Associate Director Clinical Study Lead

Senior Project Manager

Project Manager 2

Associate Clinical Project Manager

Clinical Project Manager in Investigator Initiated Studies

Senior Clinical Research Associate

Regional Clinical Research Associate

Site Manager, Clinical Research Coordinator

Director Clinical Operations

Associate Director, Clinical Operations

Associate Director, Clinical Study Lead

Clinical Operations Lead

Certified Clinical Research Associate

Clinical Research Coordinator

Clinical Operations Professional

Shea Clingerman

Senior Director & Controller, Finance

Director, Finance

Associate Director Finance

Manager of Accounting and External Reporting

Accounting Manager

Manager of Accounting and Finance

Senior Account Analyst

Senior Accountant

Staff Accountant

Sr. Director & Controller, Finance at Upstream Bio

Amy Iannelli

Associate Director, Clinical Trial Oversight Lead, Clinical Operations

Director, Clinical Assay and Biomarker Lead, Clinical Operations

Senior Scientist, Drug Metabolism and Pharmacokinetics

Senior Scientist, Clinical Hemostasis

Lead Scientist, Clinical Assays

Research Associate, Clinical Immunology

Research Associate

Casey Woodbury

Director of Supply Chain Management

Clinical Supply Lead

Cell Culture Intern/Operator

"Somewhere, something incredible is waiting to be known." - Dr. Carl Sagan

Richard Biagiotti

Advisory Board Member

Head of Technical Operations

Director, CMC/Program Management

Associate Director, Program Management

Development Engineer

Process Engineer

Biomedical Engineering Advisory Board Member

Head of Technical Operations at Upstream Bio

Parika Petaipimol

Vice President, Head of AbbVie Ventures

Senior Director & Head, Immunology Search & Evaluation

Senior Director and Head of Search and Evaluation

Senior Director, Global External R&D, BioMedicines and Tailored Therapeutics

Advisor

Senior Research Scientist

Researcher

Chief Business Officer, Upstream Bio

Director,Board of Directors

Senior Vice President, Clinical Sciences

Vice President-Late Stage Clinical Development

Vice President, Multiple Sclerosis Clinical Development

Assistant Professor Of Medicine

Medical Director, Pulmonary Function Laboratory

Medical Director, Lung Transplantation

Associate Director, Asthma Research Center

Experienced Biotechnology Executive

Chief Financial and Chief Operating Officer

Chief Financial and Chief Operating Offer

Board Member

Chief Executive Officer and Chief Finanial Officer

Chief Operating Officer and Chief Financial Officer

Chief Financial and Chief Business Officer

news impact assignment basic	general	May 6, 2024 7:53 AM	4f709766
public peers	general	May 6, 2024 7:53 AM	0bd74536
news daily refresh	general	Aug 10, 2024 6:10 AM	6b617131
news processing daily refresh	general	May 21, 2024 2:51 AM	d6925e9a
news impact assignment daily	general
news processing basic	general	May 6, 2024 7:53 AM	013efea6
company summary	general
signals	general
crunchbase trigger	general	Nov 4, 2024 10:53 AM	f4fd7ac7
crunchbase profile	general	Nov 4, 2024 11:23 AM	70006a24
li profile	general	May 6, 2024 7:53 AM	a1bdb9f6
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	3d64476b
peers	general
news basic	general	May 6, 2024 7:53 AM	89245547
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

UPB

COM:UPSTREAMBIO

Upstream Bio

Last Close

18.01

21/11 20:19

Market Cap

965.27M

Beta: -

Volume Today

227.43K

Avg: -